TABLE 3.
Responses of seropositive infants and children to cpts248/955, cpts530/1030, or cpts530/1009 mutant virus or placeboa
| RSV or placebo administered | Study | Dose (log10 PFU) | No. of subjects (% infected) | Virus isolation (nasal wash)
|
% with indicated illness
|
|||
|---|---|---|---|---|---|---|---|---|
| % Shedding virus | Mean ± SE peak titer shedb (log10 PFU/ml) | Fever | URI | LRI | ||||
| cpts248/955 | 1c | 5.0 | 13 (62) | 38 | 2.7 ± 0.64 | 15 | 7 | 0 |
| cpts530/1030 | 2 | 5.0 | 12 (50) | 42 | 1.6 ± 0.44 | 25 | 25 | 8d |
| cpts530/1009 | 3c | 5.0 | 13 (31) | 0 | ≤0.6 | 15 | 0 | 0 |
| Placebo | 1 | 0.0 | 9 (0) | 0 | ≤0.6 | 44 | 0 | 0 |
| Placebo | 2 | 0.0 | 6 (0) | 0 | ≤0.6 | 0 | 0 | 0 |
| Placebo | 3 | 0.0 | 7 (0) | 0 | ≤0.6 | 14 | 0 | 0 |
a
RSV-seropositive children and infants, 15 to 59 months old, were enrolled in these studies. Seropositive subjects had an RSV serum plaque reduction neutralizing antibody titer of >1:40. URI, upper respiratory tract illness; LRI, lower respiratory tract illness.
b
Calculated for infected subjects only.
c
See reference 16.
d
Associated with the isolation of adenovirus and thus not likely due to the RSV vaccine.